Well SI has talent at drilling...
Anyway, the key indicator for the stock will be what Novartis decides to do after looking at the results for the ARDS trial. If they decide not to proceed withe collaboration deal, I think things will get sticky for the future. Guess that decision will come in the next 30 days?
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-322
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
-0.050(4.24%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.18 | $1.13 | $2.837M | 2.476M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 267676 | $1.13 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.14 | 67813 | 27 |
View Market Depth
| Last trade - 12.43pm 17/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |